Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Current Leases (2019 - 2025)

Inmune Bio (INMB) has disclosed Current Leases for 7 consecutive years, with $623000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases rose 345.0% to $623000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $623000.0 through Dec 2025, up 345.0% year-over-year, with the annual reading at $623000.0 for FY2025, 345.0% up from the prior year.
  • Current Leases hit $623000.0 in Q4 2025 for Inmune Bio, up from $457000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $623000.0 in Q4 2025 to a low of $23000.0 in Q1 2021.
  • Historically, Current Leases has averaged $153300.0 across 5 years, with a median of $122000.0 in 2023.
  • Biggest five-year swings in Current Leases: soared 417.99% in 2021 and later crashed 35.56% in 2022.
  • Year by year, Current Leases stood at $135000.0 in 2021, then tumbled by 35.56% to $87000.0 in 2022, then skyrocketed by 36.78% to $119000.0 in 2023, then increased by 17.65% to $140000.0 in 2024, then surged by 345.0% to $623000.0 in 2025.
  • Business Quant data shows Current Leases for INMB at $623000.0 in Q4 2025, $457000.0 in Q3 2025, and $220000.0 in Q2 2025.